Analyst Reco. Pliant Therapeutics, Inc.

Equities

PLRX

US7291391057

Market Closed - Nasdaq Other stock markets 16:00:00 2024-04-26 EDT			5-day change	1st Jan Change
11.81 ^USD	-0.59%		-5.67%	-34.79%

03-12	Pliant Therapeutics, Inc. Announces Accelerated Bexotegrast Development Plan for the Treatment of Idiopathic Pulmonary Fibrosis	CI
03-05	RBC Lifts Price Target on Pliant Therapeutics to $54 From $50, Says Bexotegrast Could Have Multi-Billion-Dollar Revenue Opportunity; Outperform, Speculative Risk Kept	MT

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

RBC Lifts Price Target on Pliant Therapeutics to $54 From $50, Says Bexotegrast Could Have Multi-Billion-Dollar Revenue Opportunity; Outperform, Speculative Risk Kept	03-05	MT
RBC Cuts Price Target on Pliant Therapeutics to $50 From $53, Keeps Outperform, Speculative Risk	02-28	MT
Oppenheimer Adjusts Pliant Therapeutics Price Target to $47 From $49, Maintains Outperform Rating	02-06	MT
HC Wainwright Adjusts Pliant Therapeutics Price Target to $48 From $52, Maintains Buy Rating	02-05	MT
RBC Trims Price Target on Pliant Therapeutics to $53 From $54, Keeps Outperform, Speculative Risk	11-10	MT
HC Wainwright Adjusts Price Target on Pliant Therapeutics to $52 From $50, Maintains Buy Rating	23-09-27	MT
Oppenheimer Adjusts Pliant Therapeutics Price Target to $52 From $51, Maintains Outperform Rating	23-08-10	MT
RBC Cuts Price Target on Pliant Therapeutics to $54 From $57, Keeps Outperform Rating, Speculative Risk Qualifier	23-08-10	MT
Canaccord Genuity Initiates Pliant Therapeutics at Buy With $48 Price Target	23-05-18	MT
Oppenheimer Adjusts Pliant Therapeutics Price Target to $51 From $44, Maintains Outperform Rating	23-05-10	MT
RBC Trims Price Target on Pliant Therapeutics to $57 From $58, Maintains Outperform Rating, Speculative Risk Qualifier	23-05-10	MT
HC Wainwright Adjusts Price Target on Pliant Therapeutics to $55 From $54, Maintains Buy Rating	23-05-01	MT
Cantor Fitzgerald Adjusts Pliant Therapeutics Price Target to $63 From $52, Maintains Overweight Rating	23-05-01	MT
Baird Initiates Pliant Therapeutics at Outperform With $44 Price Target	23-04-13	MT
HC Wainwright Adjusts Price Target on Pliant Therapeutics to $54 From $53, Keeps Buy Rating	23-03-20	MT
Citigroup Adjusts Price Target on Pliant Therapeutics to $50 From $55, Maintains Buy Rating	23-03-13	MT
JPMorgan Adjusts Pliant Therapeutics Price Target to $47 From $51, Maintains Overweight Rating	23-03-10	MT
Oppenheimer Adjusts Pliant Therapeutics' Price Target to $44 From $43, Maintains Outperform Rating	23-03-10	MT
RBC Trims Price Target on Pliant Therapeutics to $58 From $60, Maintains Outperform Rating, Speculative Risk	23-03-10	MT
SVB Securities Adjusts Pliant Therapeutics' Price Target to $45 From $33, Keeps Outperform Rating	23-01-24	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Analyst Reco. Pliant Therapeutics, Inc.

Equities

PLRX

US7291391057

Analyst Reco.

Filters